Skip to main content

Advertisement

Table 2 Baseline characteristics by HIV status

From: Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women

Characteristics   HIV-positive (N = 120) n (%) HIV-negative (N = 57) n (%) P value*
Age
  < 30 years n (%) 34.0 (28.3) 11.0 (19.3) 0.27
  ≥ 30 years n (%) 86.0 (71.7) 46.0 (80.7)
Age at first intercourse
  < 18 years n (%) 36.0 (30.2) 10.0 (18.2) 0.10
  ≥ 18 years n (%) 83.0 (69.8) 45.0 (81.8)
Number of Sexual Partners
  ≤ 1 n (%) 97.0 (82.2) 48.0 (85.7) 0.67
  > 1 n (%) 21.0 (17.8) 8.0 (14.3)
Elective Abortions
 Ever n (%) 89.0 (76.7) 28.0 (56.0) 0.01*
 Never n (%) 27.0 (23.3) 22.0 (44.0)
Number of Pregnancies
  < 5 n (%) 84.0 (70.6) 30.0 (53.6) 0.04*
  ≥ 5 n (%) 35.0 (29.4) 26.0 (46.4)
Miscarriages
 Ever n (%) 9.0 (8.3) 11.0 (21.6) 0.04*
 Never n (%) 99.0 (91.7) 40.0 (78.4)
Body Mass Index (BMI), Mean (SD)   24.4 (5.2) 28.9 (6.5) 0.02*
Marital Status
 Ever Married n (%) 88.0 (73.3) 47.0 (82.5) 0.26
 Never Married n (%) 32.0 (26.7) 10.0 (17.5)
Highest Education
 Post-secondary n (%) 52.0 (43.7) 36.0 (63.2) 0.02*
  ≤ Secondary n (%) 67.0 (56.3) 21.0 (36.8)
Contraceptive use
 Ever n (%) 51.0 (42.5) 35.0 (61.4) 0.02*
 Never n (%) 69.0 (57.5) 22.0 (38.6)
Genital Lesions (Warts, Sores or Ulcers)
 Yes n (%) 9 (40.9) 5 (14.7) 0.06
 No n (%) 13 (59.1) 29 (85.3)
Follow up duration in days, Median (Interquartile Range)a   793.5 (758.0) 371.0 (274.0) <.0001*
Losses to follow-up n (%) 47.0 (28.1) 38.0 (40.0) 0.06
CD4 Count (cells/mm3)
  < 200 n (%) 22.0 (23.7) --  
  ≥ 200 n (%) 71.0 (76.3)
HAART use
 Yes n (%) 105.0 (87.5 %) --  
 No n (%) 15.0 (12.5 %)
HAART REGIMEN
 AZT-3TC-NVP n (%) 49 (53.26) --  
 EFV-TDF-3TC n (%) 18 (19.57)
 NVP-TDF-3TC n (%) 7 (7.61)
 AZT-3TC-EFV n (%) 4 (4.35)
 LPV/r-TDF-3TC n (%) 4 (4.35)
 TDF-FTC-EFV n (%) 4 (4.35)
 AZT-3TC-LPV/r n (%) 2 (2.17)
 D4T-3TC-NVP n (%) 2 (2.17)
 TDF-FTC-NVP n (%) 2 (2.17)
  1. AZT Zidovudine, 3TC Lamivudine, NVP Nevirapine, EFV Efavirenz, TDF Tenofovir, LPV/r Lopinavir/Ritonavir, FTC Emtricitabine, D4T Stavudine
  2. *Statistically significant at 0.05 level
  3. aComparison of medians was done using Wilcoxon rank-sum test